Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Alberta

$34,000.00

Investigation of the Anti-Allodynic Actions of Gabapentinoids

EF 2015-16

Résumé
SUMMARY My research seeks to understand the disruption of the normal pain processing pathways that is associated with nerve injury-induced pain. Pain is unique amongst the sensory modalities as it is the only one we usually want to block. In the case of nerve or neuropathic pain this can be acheived by the use of the ""alpha2delta ligands"", pregabalin (PGB) and gabapentin (GBP). These drugs are described as ""anti-allodynic"" as they are effective in treating touch-induced pain (allodynia) that characterizes ""neuropathic"" pain. Alpha2delta refers to an accessory subunit of voltage-gated Ca2+ channels. This subunit exhibits high affinity for gabapentinoids and is upregulated in neuropathic animals (animals showing signs of pain following experimental nerve injury). The current understanding of gabapentinoid action suggest that their binding to alpha-2-delta interferes with the ability of Ca2+ channels to interact with the vesicle fusion machinery for neurotransmitter release. This impedes transmission between nociceptive primary afferents and neurons in the superficial dorsal horn. Many aspects of gabapentinoid action remain unresolved and our ongoing studies have identified two paradoxes:- PARADOX 1. A single intraperitoneal injection of GBP suppresses signs of neuropathic pain in animal models within 30 - 60min yet most of its reported actions on neurons in vitro take 40 hours or more to develop. We seek to resolve this paradox by challenging the three specific hypotheses:- 1. The failure of gabapentinoids to exert acute effects on synaptic transmission in dorsal horn in vitro reflects the use of neurons from non-neuropathic animals. 2. Acute effects of gabapentinoids in neuropathic animals are dependent on their interaction with alpha2delta subunits. 3. Some acute spinal actions of gabapentinoids in neuropathic animals result from spinal mechanisms other than, or in addition to, depression of synaptic transmission. PARADOX II. Despite their structural similarity to GABA, gabapentinoids do not appear to affect GABAergic transmission. Because previous investigations have only looked at ""classical"" aspects of GABA function, we hypothesize:- 4. That gabapentinoids augment tonic inhibition mediated via extrasynaptic GABAA receptors in the dorsal horn. 5. That gabapentinoids interact with a novel modulatory site on the GABAB receptor. Experiments involve whole-cell recording and confocal Ca2+ imaging of rat spinal cord slices ex vivo or in organotypic culture. Molecular biological techniques and lentiviral infection will be used to manipulate levels of alpha-2-delta-1 subunits. Our studies provide insight into the action of an intriguing class of drugs by resolving paradoxes relating to their cellular and in vivo actions. Gabapentinoids also serve as a tool with which to probe the disturbances in pain processing associated with neuropathic pain and the function of GABA receptors.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2015-05881
Name nom
Smith, Peter
Department département
Pharmacology - Pharmacology
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
34000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6404
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pharmacology
Research subject fr
Pharmacologie
Partie
1
Nb partie
1
Application title
Investigation of the Anti-Allodynic Actions of Gabapentinoids
Keyword
NSERC
Application summary
<p><strong>SUMMARY</strong><br /> <br /> My research seeks to understand the disruption of the normal pain processing pathways that is associated with nerve injury-induced pain. Pain is unique amongst the sensory modalities as it is the only one we usually want to block. In the case of nerve or neuropathic pain this can be acheived by the use of the ""alpha2delta ligands"", pregabalin (PGB) and gabapentin (GBP). These drugs are described as ""anti-allodynic"" as they are effective in treating touch-induced pain (allodynia) that characterizes ""neuropathic"" pain. <br /> <br /> Alpha2delta refers to an accessory subunit of voltage-gated Ca<sup>2+</sup> channels. This subunit exhibits high affinity for gabapentinoids and is upregulated in neuropathic animals (animals showing signs of pain following experimental nerve injury). The current understanding of gabapentinoid action suggest that their binding to alpha-2-delta interferes with the ability of Ca<sup>2+</sup> channels to interact with the vesicle fusion machinery for neurotransmitter release. This impedes transmission between nociceptive primary afferents and neurons in the superficial dorsal horn. Many aspects of gabapentinoid action remain unresolved and our ongoing studies have identified two paradoxes:-<br /> <br /> <strong>PARADOX 1. A single intraperitoneal injection of GBP suppresses signs of neuropathic pain in animal models within 30 - 60min yet most of its reported actions on neurons in vitro take 40 hours or more to develop.</strong> We seek to resolve this paradox by challenging the three specific hypotheses:-<br /> 1. The failure of gabapentinoids to exert acute effects on synaptic transmission in dorsal horn <em>in vitro</em> reflects the use of neurons from non-neuropathic animals.<br /> 2. Acute effects of gabapentinoids in neuropathic animals are dependent on their interaction with alpha2delta subunits.<br /> 3. Some acute spinal actions of gabapentinoids in neuropathic animals result from spinal mechanisms other than, or in addition to, depression of synaptic transmission.<br /> <br /> <strong>PARADOX II. Despite their structural similarity to GABA, gabapentinoids do not appear to affect GABAergic transmission. </strong>Because previous investigations have only looked at ""classical"" aspects of GABA function, we hypothesize:-<br /> 4. That gabapentinoids augment tonic inhibition mediated via extrasynaptic GABA<sub>A</sub> receptors in the dorsal horn.<br /> 5. That gabapentinoids interact with a novel modulatory site on the GABA<sub>B</sub> receptor.<br /> Experiments involve whole-cell recording and confocal Ca2+ imaging of rat spinal cord slices<em> ex vivo</em> or in organotypic culture. Molecular biological techniques and lentiviral infection will be used to manipulate levels of alpha-2-delta-1 subunits. <br /> <br /> Our studies provide insight into the action of an intriguing class of drugs by resolving paradoxes relating to their cellular and <em>in vivo</em> actions. Gabapentinoids also serve as a tool with which to probe the disturbances in pain processing associated with neuropathic pain and the function of GABA receptors.</p>